Boomray Pharmaceuticals - Health Xplore

Response Research to Emerging Infectious Diseases Inform

March 26, 2024

Skin Type Before Choosing Skin Care Products

March 26, 2024

Using Lemon on Your Face & Ways to

March 26, 2024

Most Common Exercise Machines at the Gym

March 26, 2024

Contact Info

E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com

Tag: Boomray Pharmaceuticals

BoomRay, Novartis Sign Global Licence Deal for Preclinical Radioligand Therapy Asset

News

Novartis Licences Preclinical Radioligand Therapy Asset from BoomRay

BoomRay will receive up to USD 900 million, comprising an upfront payment and development, regulatory and sales milestone payments from Novartis.

imphoenix82
September 22, 2026
0 Comments
34 Views

About Us

HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.

Email: support@healthxploreindia.com

Contact: +91 9354115542

Response Research to Emerging Infectious Diseases Inform

Skin Type Before Choosing Skin Care Products

Using Lemon on Your Face & Ways to

Most Common Exercise Machines at the Gym

Contact Info

Tag: Boomray Pharmaceuticals

Novartis Licences Preclinical Radioligand Therapy Asset from BoomRay

FDA Approves IDE for Mercy’s Ovarian Cancer Screening.

Novartis Licences Preclinical Radioligand Therapy Asset from BoomRay.

Dr. Reddy’s to Distribute Takeda’s QDENGA Dengue Vaccine.

Telix to Acquire ITM in US$1.65 Billion Radiopharmaceutical.

About Us

Quick Link

Top Categories

Top Posts

Laser Treatments for Anti-aging: Types, Benefits,

Lilly’s Retatrutide Shows Powerful Weight Loss

National Registry for Implantable Medical Devices: